PMID- 15379608
OWN - NLM
STAT- MEDLINE
DCOM- 20041123
LR  - 20220309
IS  - 1568-007X (Print)
IS  - 1568-007X (Linking)
VI  - 3
IP  - 4
DP  - 2004 Aug
TI  - The MAPK/JNK signalling pathway offers potential therapeutic targets for the 
      prevention of acquired deafness.
PG  - 325-32
AB  - The c-Jun N-terminal kinases (JNKs) are also called stress activated protein 
      kinases (SAPKs) and are members of the family of mitogen activated protein 
      kinases (MAPKs). While the functions of the JNKs under physiological conditions 
      are diverse and not completely understood, there is increasing evidence that JNKs 
      are potent effectors of apoptosis of oxidative stress-damaged cells in both the 
      brain and the mammalian inner ear following a trauma. The activation of the 
      inducible transcription factor c-Jun by N-terminal phosphorylation is a central 
      event in JNK-mediated apoptosis of oxidative stress-damaged auditory hair cells 
      following exposure to either acoustic trauma or a toxic level of an 
      aminoglycoside antibiotic and also the apoptosis of auditory neurons as a 
      consequence of a loss of the trophic support provided by the auditory hair cells. 
      In this review, we summarise what is known about the expression and activation of 
      G-proteins, JNKs, c-Jun and c-Fos under oxidative stress conditions within the 
      mammalian cochlea. A particular focus is put on a new peptide conjugate that is a 
      promising protective agent(s) and pharmacological strategies for preventing 
      cochlear damage induced by both acoustic trauma and aminoglycoside ototoxic 
      damage.
FAU - Zine, A
AU  - Zine A
AD  - Universite de Montpellier I, INSERM U.583, Physiopathologie et Therapie des 
      deficits sensoriels et moteurs, 34090, France. zine@montp.inserm.fr
FAU - van de Water, T R
AU  - van de Water TR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Drug Targets CNS Neurol Disord
JT  - Current drug targets. CNS and neurological disorders
JID - 101151150
RN  - 0 (Aminoglycosides)
RN  - 0 (Peptides)
RN  - FU288768DP (D-JNKI-1)
SB  - IM
MH  - Aminoglycosides/antagonists & inhibitors/toxicity
MH  - Animals
MH  - Apoptosis/drug effects/*physiology
MH  - Deafness/drug therapy/*enzymology/physiopathology
MH  - Hair Cells, Auditory/drug effects/enzymology/pathology
MH  - Humans
MH  - MAP Kinase Signaling System/drug effects/*physiology
MH  - Nerve Degeneration/drug therapy/*enzymology/physiopathology
MH  - Noise/adverse effects
MH  - Oxidative Stress/drug effects/*physiology
MH  - Peptides/*pharmacology/therapeutic use
RF  - 58
EDAT- 2004/09/24 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/09/24 05:00
PHST- 2004/09/24 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/09/24 05:00 [entrez]
AID - 10.2174/1568007043337166 [doi]
PST - ppublish
SO  - Curr Drug Targets CNS Neurol Disord. 2004 Aug;3(4):325-32. doi: 
      10.2174/1568007043337166.